---
title: "Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Shares Sold by Lisanti Capital Growth LLC"
description: "Lisanti Capital Growth LLC has reduced its stake in Apellis Pharmaceuticals (NASDAQ:APLS) by 72.1% during Q2, selling 64,325 shares and retaining 24,885 shares. Other institutional investors also adju"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/213148695.md"
published_at: "2024-09-01T18:33:56.000Z"
---

# Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Shares Sold by Lisanti Capital Growth LLC

> Lisanti Capital Growth LLC has reduced its stake in Apellis Pharmaceuticals (NASDAQ:APLS) by 72.1% during Q2, selling 64,325 shares and retaining 24,885 shares. Other institutional investors also adjusted their holdings. Analysts have varied opinions on APLS, with four hold ratings, ten buy ratings, and a consensus target price of $54.13. Insider transactions include a sale of 37,000 shares by Director A. Sinclair Dunlop. APLS shares rose to $12.90 on Friday, with a 52-week range of $5.49 to $18.80, and the company reported a positive EPS of -$0.30 for Q2, surpassing estimates.

Lisanti Capital Growth LLC trimmed its holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 72.1% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 24,885 shares of the company's stock after selling 64,325 shares during the quarter. Lisanti Capital Growth LLC's holdings in Apellis Pharmaceuticals were worth $955,000 at the end of the most recent reporting period.

-   Beam Therapeutics Bolts Higher on Gene Therapy Licensing Payments

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in APLS. Charles Schwab Investment Management Inc. grew its stake in shares of Apellis Pharmaceuticals by 2.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 904,409 shares of the company's stock worth $54,138,000 after purchasing an additional 25,052 shares during the period. Norges Bank acquired a new position in Apellis Pharmaceuticals in the 4th quarter valued at $56,640,000. Great Lakes Advisors LLC purchased a new position in Apellis Pharmaceuticals in the 4th quarter valued at $12,461,000. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Apellis Pharmaceuticals in the first quarter worth about $3,218,000. Finally, Bellevue Group AG boosted its position in Apellis Pharmaceuticals by 3.5% during the fourth quarter. Bellevue Group AG now owns 821,800 shares of the company's stock worth $49,193,000 after acquiring an additional 27,959 shares during the last quarter. 96.29% of the stock is owned by institutional investors and hedge funds.

## Analyst Upgrades and Downgrades

APLS has been the subject of several recent research reports. Wells Fargo & Company cut their price target on Apellis Pharmaceuticals from $57.00 to $48.00 and set an "equal weight" rating for the company in a report on Thursday, May 23rd. The Goldman Sachs Group lifted their target price on shares of Apellis Pharmaceuticals from $66.00 to $74.00 and gave the stock a "buy" rating in a research note on Friday, August 9th. Piper Sandler initiated coverage on Apellis Pharmaceuticals in a research note on Friday, May 31st. They set a "neutral" rating and a $46.00 target price for the company. UBS Group decreased their target price on shares of Apellis Pharmaceuticals from $85.00 to $83.00 and set a "buy" rating on the stock in a research report on Friday, August 9th. Finally, JPMorgan Chase & Co. dropped their target price on Apellis Pharmaceuticals from $72.00 to $64.00 and set an "overweight" rating for the company in a research report on Tuesday, August 13th. Four investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $72.13.

  

-   Are Small Caps a Harbinger of Market Declines?

**View Our Latest Stock Analysis on APLS**

## Insider Transactions at Apellis Pharmaceuticals

In other Apellis Pharmaceuticals news, Director A. Sinclair Dunlop sold 37,000 shares of the company's stock in a transaction dated Friday, June 21st. The shares were sold at an average price of $39.24, for a total transaction of $1,451,880.00. Following the transaction, the director now directly owns 136,998 shares in the company, valued at $5,375,801.52. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 6.80% of the company's stock.

## Apellis Pharmaceuticals Stock Performance

Shares of APLS traded up $0.18 during mid-day trading on Friday, hitting $38.90. 636,078 shares of the company's stock were exchanged, compared to its average volume of 1,355,396. The company has a debt-to-equity ratio of 1.73, a current ratio of 5.08 and a quick ratio of 4.18. Apellis Pharmaceuticals, Inc. has a fifty-two week low of $33.49 and a fifty-two week high of $73.80. The business's 50 day moving average is $37.94 and its two-hundred day moving average is $46.71.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last released its earnings results on Thursday, August 1st. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.33) by $0.03. The business had revenue of $199.70 million for the quarter, compared to analyst estimates of $190.89 million. Apellis Pharmaceuticals had a negative return on equity of 138.32% and a negative net margin of 52.99%. The company's revenue for the quarter was up 110.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.02) earnings per share. On average, analysts expect that Apellis Pharmaceuticals, Inc. will post -1.28 earnings per share for the current year.

## Apellis Pharmaceuticals Profile

(Free Report)

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).

## Featured Stories

-   Five stocks we like better than Apellis Pharmaceuticals
-   How to Evaluate a Stock Before Buying
-   Don’t Overlook Campbell Soup: Here’s What Could Drive Its Stock
-   Investing In Preferred Stock vs. Common Stock
-   Birkenstock’s Sudden Slide—Why It Might Be Your Next Big Win
-   What is the NASDAQ Stock Exchange?
-   MarketBeat Week in Review – 8/26 - 8/30

**Want to see what other hedge funds are holding APLS?** Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report).

*This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.*

→ Ex WH Advisor Who Predicted Biden Leaving Race Makes Startling New Prediction (From Paradigm Press) (Ad)## Should you invest $1,000 in Apellis Pharmaceuticals right now?

Before you consider Apellis Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Apellis Pharmaceuticals wasn't on the list.

While Apellis Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

### Related Stocks

- [APLS.US - Apellis Pharma](https://longbridge.com/en/quote/APLS.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 安斯泰莱制药的 Izervay 活动将医疗保健专业人士视为 “保护的伙伴” | 安斯泰莱制药推出了 “保护伙伴” 宣传活动，旨在教育视网膜专家在管理患者的地理萎缩（GA）中所扮演的重要角色。该活动展示了真实的医生与患者配对参与爱好，强调在 GA 治疗中需要转变思维方式。它鼓励早期干预，并旨在提高医生和患者对治疗选择的认 | [Link](https://longbridge.com/en/news/275936312.md) |
| Apellis Pharmaceuticals, Inc. $APLS 的股份被 Savant Capital LLC 出售 | Savant Capital LLC 在第三季度减少了对 Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) 的持股比例，降幅为 50.7%，目前持有 48,886 股，价值 110 万美元。其他投资者 | [Link](https://longbridge.com/en/news/275591859.md) |
| Apellis 首席执行官 Cedric Francois 报告出售公司普通股 | Apellis Pharmaceuticals Inc. 的首席执行官 Cedric Francois 报告了公司普通股的出售。完整的文件可以通过提供的链接获取。此消息由 Public Technologies 生成，仅供参考，不应被视为财 | [Link](https://longbridge.com/en/news/273555525.md) |
| Apellis Pharmaceuticals：欧洲 Aspaveli 的验证以及美国 C3G/IC-MPGN 的增长势头支撑了买入评级 | 威廉·布莱尔分析师拉赫兰·汉伯里·布朗对 Apellis Pharmaceuticals (APLS) 维持买入评级，原因是 Aspaveli 最近获得欧洲对 C3G 和 IC-MPGN 的批准，这增强了公司的全球定位。他指出，尽管短期内财 | [Link](https://longbridge.com/en/news/272856422.md) |
| Apellis 首席执行官 Cedric Francois 报告了出售普通股的情况 | Cedric Francois，Apellis Pharmaceuticals Inc. 的首席执行官，已报告出售该公司的普通股。完整的文件可通过提供的链接获取。此消息由公共技术公司生成，仅供参考，不应被视为财务、投资或法律建议。Apell | [Link](https://longbridge.com/en/news/272748153.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
